The Standard Co., Ltd., founded in South Korea in 2006, designs, manufactures, and services advanced medical devices with a singular focus on quality and precision. Through a disciplined culture of creative problem-solving and technology-driven innovation, the company delivers solutions that comply with stringent international standards and earn the trust of healthcare professionals worldwide. Its portfolio spans critical devices, including endoscopic markers and electrophysiology catheters, and is reinforced by comprehensive in-house laboratory capabilities for testing, validation, and cleanroom-regulated manufacturing.
Guided by a customer-centric philosophy, The Standard prioritizes long-term value creation and sustained partnerships with clients, collaborators, and employees. Moreover, by integrating safety, accuracy, and robust process control into every stage of development, the company consistently achieves high performance and regulatory compliance in demanding clinical environments. As a result, The Standard has established itself as a reliable provider of high-performance medical technology across both domestic and global markets.
In an exclusive interaction with The Interview World at Medical Fair India 2026, Harry Lee, Sales Manager at The Standard Co., Ltd., offers a comprehensive perspective on the company’s innovative endoscopic markers, evaluates India’s strategic importance as a growth market, outlines the product roadmap for the coming decade, and highlights the accelerating global demand for these technologies.
The following are the key takeaways from this insightful and forward-looking conversation.
Q: Could you provide an overview of your medical product portfolio and discuss how these products are deployed across diagnostic use cases?
A: The Standard Co., Ltd. is a South Korean medical device manufacturer with a growing global footprint. At present, the company exports two flagship products, Black Eye and Blue Eye, both engineered as advanced endoscopic markers for precision-driven clinical use.
Black Eye enables accurate lesion marking by depositing high-contrast black ink directly at the target site. As a result, clinicians can clearly identify and relocate the exact lesion during subsequent procedures. In contrast, Blue Eye facilitates lesion resection by injecting a specialized solution beneath the tissue, effectively lifting the lesion and creating optimal separation. This elevation allows physicians to remove the lesion more efficiently and safely using a snare.
Together, these complementary solutions enhance procedural accuracy and ease of use. Consequently, The Standard now supplies these products to healthcare systems in more than 70 countries worldwide, reflecting strong global demand and clinical confidence in its technology.
Q: What has been your assessment of India as a market for your products?
A: At present, we are actively seeking a distributor in India, as the market remains open and strategically attractive to us. Therefore, we chose to participate in this exhibition to establish partnerships, assess market dynamics firsthand, and lay the groundwork for a strong commercial presence in the country.
Q: Which new product areas or innovations is your company prioritizing over the next decade?
A: We are actively exploring the development of a new generation of products. Looking ahead three to five years, we aim to introduce two to three advanced solutions, with a particular focus on hemostatic applications that address critical unmet clinical needs.
Q: What is the global demand for these products?
A: Our products command a good market share, underscoring our strong position in this specialized field. Our customer base spans major public and government hospitals as well as leading private healthcare institutions. In particular, we serve established markets across the United States and key European countries, including the United Kingdom, the Netherlands, Spain, and Germany, among the largest and most influential healthcare markets in the region.
